Drugs / JNJ-37822681
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00728195 | Nov 2008 → Feb 2010 | schizophrenia | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 2 | NCT01812642 | Jul → Dec 2008 | schizophrenia | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-37822681 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00728195 ↗ |
| Action | Inhibit | “for the selective fast-dissociating D2 receptor antagonist JNJ-37822681” PMID 22995972 ↗ Sep 20121“Dopamine D2 receptor antagonist” CHEMBL3234237 ↗ |
| Modality | Small molecule | — CHEMBL3234237 ↗ |
| Route | Oral | “JNJ-37822681 capsule 10 mg orally twice a day” NCT00728195 ↗ |
| Target | DRD2 | “Dopamine D2 receptor antagonist” CHEMBL3234237 ↗ |